CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 125 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $478,000 | +18.0% | 61,800 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $405,000 | -12.3% | 61,800 | -11.1% | 0.00% | 0.0% |
| Q3 2020 | $462,000 | -20.2% | 69,500 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $579,000 | +8.6% | 69,500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $533,000 | -5.0% | 69,500 | +3.0% | 0.00% | +100.0% |
| Q4 2019 | $561,000 | +12.7% | 67,500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $498,000 | -28.6% | 67,500 | +8.7% | 0.00% | -50.0% |
| Q2 2019 | $697,000 | +6.7% | 62,100 | +2.3% | 0.00% | 0.0% |
| Q1 2019 | $653,000 | -5.2% | 60,700 | +33.1% | 0.00% | 0.0% |
| Q4 2018 | $689,000 | -5.2% | 45,600 | +16.0% | 0.00% | 0.0% |
| Q3 2018 | $727,000 | -19.0% | 39,300 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $898,000 | +50.4% | 39,300 | +87.1% | 0.00% | +50.0% |
| Q1 2018 | $597,000 | +34.8% | 21,000 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $443,000 | +16.0% | 21,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $382,000 | +17.5% | 21,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $325,000 | – | 21,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |